[A17-50] Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2018
Commission awarded on 29.09.2017 by the Federal Joint Committee (G-BA).
Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
Patients for whom treatment with docetaxel, pemetrexed or nivolumab is indicated: indication of a major added benefit (PD-L1 high) or non-quantifiable added benefit (PD-L1 low) Other patients: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.